Current Report Filing (8-k)
March 18 2020 - 5:10PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
March 12, 2020
Date of report (Date of earliest event reported)
GENPREX, INC.
(Exact name of registrant as specified in its charter)
Delaware
|
001-38244
|
90 - 0772347
|
(State or other jurisdiction of
incorporation or organization)
|
(Commission File Number)
|
(I.R.S. Employer
Identification Number)
|
|
|
|
1601 Trinity Street, Suite 3.322, Austin, TX
|
|
78712
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including area code: (512) 537-7997
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange on which registered
|
Common Stock, par value $0.001 per share
|
|
GNPX
|
|
The Nasdaq Capital Market
|
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b–2 of the Securities Exchange Act of 1934 (§ 240.12b–2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 3.02 Unregistered Sales of Equity Securities.
On October 1, 2019, Genprex, Inc. (the "Company") issued 5,000 shares of our common stock to a consultant in consideration of services provided by the consultant.
On December 4, 2019, the Company issued 248,000 shares of our common stock to a consultant in consideration of services provided by the consultant.
On January 2, 2020, the Company issued 5,000 shares of our common stock to a consultant in consideration of services provided by the consultant.
On January 25, 2020, the Company granted stock options under our 2018 Equity Incentive Plan to purchase up to an aggregate of 40,000 shares of our common stock to our key service providers, with an exercise price of $1.28 per share.
On March 12, 2020, the Company granted stock options under our 2018 Equity Incentive Plan to purchase up to an aggregate of 1,090,000 shares of our common stock to our employees, with an exercise price of $2.00 per share.
Each of the issuances described above was made pursuant to an exemption from the registration requirement of the Securities Act provided in Section 4(a)(2) of the Securities Act and/or Regulation D thereunder.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
GENPREX, INC.
|
|
|
|
|
|
Date: March 18, 2020
|
By:
|
/s/ Ryan Confer
|
|
|
|
Ryan Confer
|
|
|
|
Chief Financial Officer
(Principal Financial Officer)
|
|
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Sep 2023 to Sep 2024